Assistant Professor, Oncology, Mayo Medical School
Hematology
Dr. John A. Laurie, MD
|
|
Give Review
John Laurie practices Hematology. He graduated from University of Edinburg Medical School. Dr. John A. Laurie is also published. He has 33 publications published. The lastest publication: "Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North C...' He accepts all Medicare patients.
Publications
- Prognostic impact of microsatellite instability and DNA ploidy in human colon Carcinoma patients.
- Thymidylate synthase expression in colon Carcinomas with microsatellite instability.
- A method for scoring denture plaque.
- The treatment of Carcinoma of the cervix uteri, stages I and II, with radium and 4 MeV supplementary x rays. A preliminary communication.
- Fine structure of a radiation-induced osteogenic sarcoma.
- A comparison of remote afterloading and manually inserted caesium in the treatment of Carcinoma of cervix.
- Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
- A new graphic for quality adjusted life years (Q-TWiST) survival Analysis: the Q-TWiST plot.
- Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity.
- Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon Cancer.
- Pilot study of accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage III non-small Cell lung carcinoma.
- Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.
- An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon Cancer.
- Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.
- Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon Carcinoma: a final report.
- Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast Cancer and prior chemotherapy exposure.
- Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast Cancer.
- A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung Cancer.
- Phase II study of the combination of carmustine and 6-thioguanine in advanced malignant melanoma.
- Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenoCarcinoma.
- A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in coloRectal carcinoma.
- Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment ...
- Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian Carcinoma: a comparison of equally myelosuppressive regimens.
- Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced coloRectal carcinoma.
- Levamisole and fluorouracil for adjuvant therapy of resected colon Carcinoma.
- Surgery for recurrent colon Cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North C...
- Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon Cancer.
- An evaluation of postoperative follow-up tests in colon Cancer patients treated for cure.
- A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal Cancer.
- Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
- A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo C...
- Chemotherapy for hormonally refractory advanced prostate Carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluoroura...
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Edinburg Medical School
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1326027384 | |
| NPPES Provider LastName | LAURIE | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 911.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 64.0 | |
| Percent Opioid Claims | 7.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326027384 |
| Last Name Of The Provider | LAURIE |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Kevin P. McKian, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven R. Zeldenrust, MD |